Protas is pleased to announce the appointment of Dr Beth Thompson MBE to its board.
Beth has over 10 years’ experience working on clinical and regulatory policy and she has led Wellcome’s Policy team since 2017, during which time she has delivered and championed better public policy for science and health globally. Her work has focussed on leading issues including Brexit, research investment, regulation of emerging technologies and the culture of research.
Beth was awarded an MBE in 2017 for her services to science for her work on the EU General Data Protection Regulation. She holds a PHD in biochemistry and genetics from the MRC Laboratory of Molecular Biology and University of Cambridge.
The Board of Directors brings broad expertise from academic, clinical, corporate and industry backgrounds and it will be further strengthened by her invaluable expertise on the regulation and governance of health research.
Commenting on this appointment, Lord Prior, Chairman of the Board said: “We are delighted to welcome Beth to the board of Protas. Her unique expertise on policy and advocacy in global public health will be a great asset for the organisation and it will enable us to realise our ambitious to design and deliver smarter clinical trials for better health across the world.”